Kris F. Sachsenmeier is a seasoned expert in translational science with substantial experience in oncology. Currently serving as Vice President and Head of Translational Science at Compass Therapeutics Inc., Kris has held prominent positions at notable companies including Takeda Oncology, where Kris led the Oncology Translational Strategy: Cold-to-Hot, and AstraZeneca as Associate Director of Translational Science in IMED Oncology. Kris's career also includes a role as Senior Scientist in Oncology Research at MedImmune, an AstraZeneca Company, and as Senior Scientist - Head of Antibody Discovery at Arius Research Inc. Kris holds a Ph.D. in Toxicology and a Master of Science in Medical Microbiology and Immunology, both from the University of Wisconsin-Madison.
October, 2023 - present